Related references
Note: Only part of the references are listed.Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Lawrence H. Young et al.
CIRCULATION (2018)
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies
Raminderjit Kaur et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Translating aetiological insight into sustainable management of type 2 diabetes
Roy Taylor et al.
DIABETOLOGIA (2018)
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Meng Lee et al.
STROKE (2017)
Insulin action and resistance in obesity and type 2 diabetes
Michael P. Czech
NATURE MEDICINE (2017)
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke orMyocardial Infarction
Walter N. Kernan et al.
JAMA NEUROLOGY (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Elena Filipova et al.
DIABETES THERAPY (2017)
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Elena Filipova et al.
DIABETES THERAPY (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Mayer B. Davidson
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Ilia Goltsman et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Xiao-Wu Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
H. Florez et al.
DIABETES OBESITY & METABOLISM (2015)
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
James D. Lewis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
Ann V. Schwartz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
Shoko Horita et al.
PPAR RESEARCH (2015)
PPARγ Agonist-Induced Fluid Retention Depends on αENaC Expression in Connecting Tubules
Yiling Fu et al.
NEPHRON (2015)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metformin-mode of action and clinical implications for diabetes and cancer
Ida Pernicova et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Gerald I. Shulman
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Richard G. Bach et al.
CIRCULATION (2013)
Panel Recommends Easing Restrictions on Rosiglitazone Despite Concerns About Cardiovascular Safety
Mike Mitka
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
Catherine A. Bourg et al.
ANNALS OF PHARMACOTHERAPY (2012)
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Z. Punthakee et al.
DIABETOLOGIA (2012)
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
A. Neumann et al.
DIABETOLOGIA (2012)
Chemical Proteomics-Based Analysis of Off-Target Binding Profiles for Rosiglitazone and Pioglitazone: Clues for Assessing Potential for Cardiotoxicity
Brian R. Hoffimann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol
E. L. Lim et al.
DIABETOLOGIA (2011)
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
Ralph A. DeFronzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Macrophages, Inflammation, and Insulin Resistance
Jerrold M. Olefsky et al.
ANNUAL REVIEW OF PHYSIOLOGY (2010)
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Hertzel C. Gerstein et al.
CIRCULATION (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Rosiglitazone and the Case for Safety Over Certainty
David N. Juurlink
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Thiazolidinedione Drugs and Cardiovascular Risks A Science Advisory From the American Heart Association and American College of Cardiology Foundation
Sanjay Kaul et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Revisiting the Rosiglitazone Story - Lessons Learned
Clifford J. Rosen
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Obesity, Inflammation, and Insulin Resistance - A Mini-Review
Maximilian Zeyda et al.
GERONTOLOGY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Fat and beyond: The diverse biology of PPAR gamma
Peter Tontonoz et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Management of Hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2008)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Mark A. Deeg et al.
DIABETES CARE (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure
David Aguilar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure
Henry J. Dargie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke - Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
Robert Wilcox et al.
STROKE (2007)
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
Philippe Gervois et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Disordered lipid metabolism and the pathogenesis of insulin resistance
David B. Savage et al.
PHYSIOLOGICAL REVIEWS (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease
James B. Meigs et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Islet β cell failure in type 2 diabetes
Marc Prentki et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Therapeutic roles of peroxisome proliferator-activated receptor agonists
B Staels et al.
DIABETES (2005)
Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome - A summary of the evidence
ES Ford
DIABETES CARE (2005)
Treatment of insulin resistance in diabetes mellitus
HE Lebovitz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes
D Choi et al.
DIABETES CARE (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study
TE Delea et al.
DIABETES CARE (2003)
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
CM Alexander et al.
DIABETES (2003)
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
J Sakamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
PPARγ and the treatment of insulin resistance
JM Olefsky et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2000)
Share Paper
